Immunophotonics co-founders Lu Alleruzzo (CEO), Tomas Hode, PhD (CIO and President), and David Anderson, PhD (CSO) are excited to be attending CIRSE 2024 Congress taking place in Lisbon, Portugal, September 14th to 18th and ESMO Congress in Barcelona, Spain on September 16th. They look forward to engaging with fellow professionals, discussing the latest advancement in...
Immunophotonics won the Startup World Cup St. Louis Regional finals. A big thank you to Emily Hemingway and her team at TechSTL for their hard work in organizing this remarkable event. You did an exceptional job! We also want to extend our gratitude to the judges—Vikram Lakhwara, Atul Kamra, Rick Holton Jr., and Julia Campbell—for...
We are thrilled to announce that Dr. Robert Martin has successfully enrolled and treated the first patient in our groundbreaking clinical trial: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of IP-001 as Adjuvant Therapy in Participants with Hepatocellular Carcinoma after Complete Radiological Response following Surgical Resection and Local Ablation or Local...
Immunophotonics is excited to share that Wei Chen, co-inventor of IP-001, Stephenson Chair, professor and interim director of the Stephenson School of Biomedical Engineering and his team recently organized a session titled “Immunophotonics” for the Gordon Research Conference Optics and Photonics in Medicine and Biology in Lewiston, Maine. During this session, Professor Chen delivered an...
Immunophotonics is excited to be featured in Pharma Tech Outlook magazine in the Immunotherapy edition. Immunophotonics innovative approach could transform standard treatments into powerful immunotherapies with IP-001 turning every procedure into an opportunity to mobilize the body’s natural immune system against cancer. “A New Frontier in Treating Cancer: The Great Potential of Interventional Immuno-Oncology™ Link...
Immunophotonics is excited to announce that a leading academic medical center that combines high-quality complex patient care with innovative scientific research, received authorization to proceed with recruitment to conduct a clinical trial combining Immunophotonics’ investigational drug IP-001 with AngioDynamics’ advanced ablation devices. This trial will explore the power of IP-001 following thermal ablation or irreversible...
Lu Alleruzzo, CEO, Tomas Hode, PhD, CIO, and President, along with the Immunophotonics Team, extend their congratulations to Professor Wei Chen, co-inventor of IP-001, for being honored as one of the Class of 2024 Senior Members by the National Academy of Inventors (NAI). Professor Chen is getting recognized for his significant contributions to biomedical engineering...
Immunophotonics is excited to share that Dr. Robert CG Martin II, M.D, PhD, PACS, who serves as Principal Investigator and National Coordinating Investigator at the University of Louisville for Immunophotonics’ Phase 2 clinical trial, will be presenting his IRE data at the Central Surgical Association 81st Annual Meeting taking place June 6 – 8, 2024,...
Immunophotonics co-founders Lu Alleruzzo (CEO) and Tomas Hode, PhD (CIO and President) will be in Chicago at the ASCO (American Society of Clinical Oncology) annual meeting, May 31 – June 3, 2024, taking place at the McCormick Place convention center. They are thrilled to engage with clinical experts worldwide, explore cutting-edge research, and discover innovative...
Immunophotonics, Inc. is delighted to introduce Jacqueline Hess as the newest addition to our advisory board. Ms. Hess has over 25 years of Big 4 experience supporting U.S. biotech companies that are expanding globally, with a particular focus on the U.S.-Swiss business corridor. Jacqueline is dedicated to helping life sciences companies thrive and achieve their mission of helping...
